DWYER, Michael, Timothy GUZI, Kamil PARUCH, Ronald DOLL, Kartik KEERTIKAR and Viyyoor GIRIJAVALLABHAN. Pyrazolopyridines as Cyclin-Dependent Kinase Inhibitors. 2004.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Pyrazolopyridines as Cyclin-Dependent Kinase Inhibitors
Name in Czech Pyrazolopyridines as Cyclin-Dependent Kinase Inhibitors
Authors DWYER, Michael (840 United States of America), Timothy GUZI (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor), Ronald DOLL (840 United States of America), Kartik KEERTIKAR (840 United States of America) and Viyyoor GIRIJAVALLABHAN (840 United States of America).
Edition Number: WO 2004/026872 A1, Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering-Plough, 2004.
Other information
Original language English
Type of outcome Patent
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/04:00035989
Organization unit Faculty of Science
Keywords (in Czech) cyclin dependent kinase; inhibitor; pyrazolopyrimidine
Keywords in English cyclin dependent kinase; inhibitor; pyrazolopyrimidine
Tags Cyclin dependent kinase, inhibitor, pyrazolopyrimidine
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 25/6/2009 09:52.
Abstract
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyridine compds. I [R = (un)substiuted-alkyl, -aryl, -heteroaryl, -heteroarylalkyl, etc.; R1 = H, alkyl or aryl; R2 = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -aryl, etc.; R3 = H, halo, CF3, (un)substituted-alkyl, -aryl, etc.; R4 = H, halo, CF3, (un)substituted-alkyl, -cycloalkyl, -aryl, -heteroaryl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by condensation of 7-amino-5-phenylpyrazolo[1,5-a]pyridine (prepn. given) with 3-formylpyridine. I possessed excellent CDK inhibitory properties as demonstrated by the IC50 value for III of 0.078 .mu.M in inhibition of CDK2.
Abstract (in Czech)
viz Anotace
PrintDisplayed: 2/8/2024 23:16